Toxicity was higher with I + C + B; rates of grade 3-5 adverse events, serious adverse events, and treatment discontinuation were all significantly increased compared to I + C. <b>Conclusions:</b> In the first-line treatment of advanced EGFR/ALK-negative non-squamous NSCLC, adding bevacizumab to I + C improved PFS but did not translate into an OS gain. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.